A computational evaluation of FDA medicines’ ability to inhibit hypoxia-inducible factor prolyl hydroxylase-2 (PHD-2) for acute respiratory distress syndrome
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.